Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for BridgeBio Pharma (BBIO) over the last 5 years, with Dec 2024 value amounting to $186.1 million.

  • BridgeBio Pharma's Shares Outstanding (Diluted Average) rose 1.77% to $191.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.9 million, marking a year-over-year increase of 1.77%. This contributed to the annual value of $186.1 million for FY2024, which is 14.30% up from last year.
  • BridgeBio Pharma's Shares Outstanding (Diluted Average) amounted to $186.1 million in FY2024, which was up 14.30% from $162.8 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Shares Outstanding (Diluted Average) ranged from a high of $186.1 million in FY2024 and a low of $118.0 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $162.8 million (2023), whereas its average is $165.4 million.
  • Data for BridgeBio Pharma's Shares Outstanding (Diluted Average) shows a peak YoY rose of 22.34% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Shares Outstanding (Diluted Average) stood at $118.0 million in 2020, then rose by 22.34% to $144.4 million in 2021, then rose by 2.16% to $147.5 million in 2022, then climbed by 10.39% to $162.8 million in 2023, then rose by 14.30% to $186.1 million in 2024.